Case Page


Case Status:    SETTLED
On or around 02/14/2011 (Date of order of final judgment)

Filing Date: November 10, 2009

According to the complaint, Hemispherx is a biopharmaceutical company engaged in the clinical development, manufacture, marketing and distribution of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based chronic disorders. The Company's products include Ampligen, an experimental drug undergoing clinical development for the treatment of chronic fatigue syndrome.

The complaint alleges that, during the Class Period, defendants misled investors regarding the status of Hemispherx's New Drug Application ("NDA") for Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, defendants failed to disclose and misrepresented the fact that the FDA had requested several reports from the Company before the NDA could even be considered, thus delaying the possible approval of Ampligen by several months at a minimum. On November 2, 2009, when the Company belatedly disclosed this information, the per share price of Hemispherx's common stock dropped from $1.45 on the previous day to $1.13, a drop of more than 20%. The next day, one commenter characterized the November 2nd Company "update" as essentially an admission "that its prior public statements were false and misleading."

On February 12, 2010, Judge Paul S. Diamond consolidated several actions under lead case, In re Hemispherx Biopharma, Inc. Litigation, Civil Action No. 09-5262, and granted the motion for approval of lead plaintiff and lead counsel. The Hemispherx Investor Group was appointed lead plaintiff and the law firms of Berger Montague and Brower Piven as its lead counsel were approved as lead counsel. On March 1, 2010, the lead plaintiff filed a Consolidated Class Action Complaint. On March 12, 2010, the defendants filed a motion to dismiss. On April 20, 2010, the defendants’ motion to dismiss was denied.

According to a press release dated August 24, 2010, Hemispherx Biopharma, Inc. announced that, as result of court mediation proceedings, it has entered into a written agreement in principle with the Court-appointed lead plaintiffs to settle all of the currently pending securities class actions consolidated in the U.S. District Court for the Eastern District of Pennsylvania. The proposed settlement requires formal court approval. The class actions have been stayed by the Court pending those mandatory procedures needed to formalize and approve the settlement. The settlement will be paid from the company's insurance coverage and will not result in the payment of any funds by the Company. Furthermore, the settlement expressly is not an admission of any culpability by Hemispherx or its officers.

On September 24, 2010, a motion for preliminary approval of settlement was filed.

According to a press release dated November 16, 2010, pursuant to Rule 23 of the Federal Rules of Civil Procedure and by Order of the United States District Court for the Eastern District of Pennsylvania dated October 20, 2010, a hearing will be held on January 20, 2011 at 10:00 a.m. in Courtroom 6B, United States Courthouse, 601 Market Street, Philadelphia, PA 19106, to determine (1) whether the proposed Settlement (the "Settlement") of the above-captioned action ("Action") for $3,600,000 should be approved by the Court as fair, reasonable, and adequate; (2) whether the motion of Co-Lead Counsel for an award of attorneys' fees and reimbursement of expenses should be approved; and (3) whether the Action should be dismissed with prejudice.

On February 14, 2011, the settlement was approved and the action was dismissed with prejudice.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: HEB
Company Market: American SE
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: E.D. Pennsylvania
DOCKET #: 09-CV-05262
JUDGE: Hon. Paul S. Diamond
DATE FILED: 11/10/2009
CLASS PERIOD END: 10/30/2009
  1. Dyer & Berens LLP (former)
    682 Grant Street, Dyer & Berens LLP (former), CO 80203-3507
    303.861.1764 303.861.1764 ·
  2. Holzer Holzer & Fistel, LLC (Atlanta)
    200 Ashford Center North, Suite 300, Holzer Holzer & Fistel, LLC (Atlanta), GA 30338
    770.392.0090 770.392.0090 ·
  3. Law Offices of Bernard M. Gross (Philadelphia)
    John Wanamaker Building; 100 Penn Square East, Suite 450, Law Offices of Bernard M. Gross (Philadelphia), PA 19107
    215.561.3600 215.561.3600 ·
No Document Title Filing Date
COURT: E.D. Pennsylvania
DOCKET #: 09-CV-05262
JUDGE: Hon. Paul S. Diamond
DATE FILED: 03/01/2010
CLASS PERIOD END: 12/01/2009
  1. Berger & Montague PC
    1622 Locust Street, Berger & Montague PC, PA 19103
    800.424.6690 215.875.4604 ·
  2. Brower Piven (Baltimore)
    The World Trade Center-Baltimore. 401 East Pratt Street, Suite 2525, Brower Piven (Baltimore), MD
    410.332.0030 410.685.1300 ·
  3. Brower Piven (New York)
    488 Madison Avenue. Eighth Floor, Brower Piven (New York), NY 10022
    212.501.9000 212.501.0300 ·
No Document Title Filing Date